CNX and Klaria tee up European launch for new migraine drug

13 January 2025

CNX Therapeutics has signed a license agreement with Klaria Pharma (Nasdaq First North: KLAR) to market and sell the migraine drug sumatriptan aginate in Europe.

The product is an innovative formulation which uses Klaria’s patented alginate film technology, designed for fast and reliable oral administration.

The agreement includes up-front and milestone payments totaling up to 2 million euros ($2.1 million), with royalties based on revenues. CNX plans to launch the treatment in Germany, Spain and Italy by late 2025, expanding to additional European markets in 2026.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical